Radiolabeled Monoclonal Antibody, Paclitaxel, and Interferon Alfa in Treating Patients With Recurrent Ovarian Cancer
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Phase I trial to study the effectiveness of radiolabeled monoclonal antibody, paclitaxel, and
interferon alfa in treating patients who have ovarian cancer. Radiolabeled monoclonal
antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to
them without harming normal cells. Drugs used in chemotherapy use different ways to stop
tumor cells from dividing so they stop growing or die. Interferon may interfere with the
growth of cancer cells. Combining monoclonal antibody, chemotherapy, and interferon alfa may
kill more tumor cells.